Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32

Alliance Global Partners has initiated coverage on Immunome (NASDAQ: IMNM) with a Buy rating. The firm has set a price target of $32 for the company's stock.